Characterizing a Population with Severe Manifestations of Sickle Cell Disease Using U.S. Real-World Evidence

ConclusionsBased on this contemporary real-world evidence from the U.S. setting, a substantial proportion of patients with SCD experience a diverse set of severely debilitating complications of the disease, as well as other co-morbidities associated with the disease. The high rate of comorbidities across all age groups and overrepresentation of patients younger than 30 years of age (relative to age distribution of general U.S. population) indicate that patients with SCD still experience significant morbidity and early mortality with current standard medical care. Given the notable heterogeneity of the clinical manifestations of SCD, future treatment approaches should address the root cause of the disease.DisclosuresParamore: bluebird bio: Employment, Equity Ownership. Kong: bluebird bio: Consultancy, Research Funding. Minegishi: bluebird bio: Employment, Equity Ownership. Shi: bluebird bio: Employment, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Paramore, C., Kong, A., Minegishi, S., Shi, W. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster III Source Type: research